Abstract
Background Immunologic heterogeneity is known to exist within both eczematous dermatitis and psoriasis; however, selection of molecularly targeted therapies for individual patients generally does assess for or incorporate such information about patient-specific immune changes.
Objective We sought to develop a rapid, non-invasive method for obtaining and analyzing epidermal protein biomarkers from skin and utilize this methodology to dissect immunologic heterogeneity in both psoriasis and eczematous dermatitis.
Methods We optimize and evaluate detergent-based immune profiling system (DIPS) which utilizes a combination of two detergents to solubilize full-thickness epidermis when applied to the skin with an applicator. Downstream proteomic profiling of this material allows high-throughput immunologic characterization of immune biomarkers.
Results DIPS was performed on 43 patients with psoriasis and 27 patients with eczematous dermatitis. This approach was found to be painless, nonscarring, and enabled rapid turnaround from sample collection to data output. We used this approach to accurately differentiate psoriasis and eczema using a limited set of proteins and to identify cases of eczema/psoriasis overlap with non-canonical molecular profiles. Additionally, we measured patient-specific cytokine profiles in eczema that correlated with response to IL-4Rα blockade.
Conclusion DIPS is a promising new non-invasive cutaneous immune profiling approach that can deconvolute immune heterogeneity amongst patients with both psoriasis and eczematous dermatitis.
Clinical Implication DIPS has potential applications in both research and day-to-day dermatologic practice and may help personalize diagnosis and medication selection in patients with inflammatory skin diseases.
Capsule summary Detergent-based immune profiling system (DIPS), a novel non-invasive approach for molecular evaluation of skin disease, is described and evaluated in psoriasis and eczematous dermatitis
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Colton Center for Autoimmunity at Yale
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Yale Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding sources: This work was supported by the Colton Center for Autoimmunity at Yale.
Conflicts of Interest: Yale University (MJM, JMC, WD) has filed a preliminary patent application related to this work. WD is a consultant for Pfizer, Incyte, Eli Lilly, and TWi Biotechnology, has research funding from Pfizer, Advanced Cell Diagnostics/Bio-techne, and AbbVie and receives licensing fees from EMD/Millipore/Sigma, all outside the submitted work. JMC serves on a data and safety monitoring board (DSMB) for Advarra. MJM, GC, PE, AMW, and SLS have no conflicts to disclose.
Abbreviations
- BN surfactant
- equimolar ratio (0.5% w/v each) of Brij-30 and N-decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate
- BSA
- body surface area
- CCL
- CC chemokine ligand
- CXCL
- C-X-C motif chemokine ligand
- DEP
- differentially expressed protein
- DIPS
- detergent-based immune profiling system
- IFN
- interferon
- IGA
- Investigator’s Global Assessment
- IL
- interleukin
- JAK
- Janus kinase
- LR
- logistic regression
- PC
- principal component
- RFE
- recursive feature elimination
- TNF
- tumor necrosis factor
- TYK2
- tyrosine kinase 2
- UMAP
- uniform manifold approximation and projection
- vIGA-AD
- validated Investigator’s Global Assessment for Atopic Dermatitis
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos